A Study to Evaluate the Safety, Tolerability, and Immunogenicity of the rSm-p80 + GLA-SE (SchistoShield®) Candidate Vaccine in Healthy Adults in Burkina Faso and Madagascar

NCT05762393 · clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
120
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

International Vaccine Institute